Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

#2215

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Aim(s): To develop a novel low-cost multiplex biomarker assay to stratify PanNETs into molecular subtypes with distinct prognosis and grades.

Materials and methods: Primary untreated PanNET fresh-frozen samples (n=157) were profiled for 198 PanNETassigner genes using NanoString platform to develop NanoPanNETassigner assay. Concordance between RNAseq and NanoPanNETassigner subtypes was assessed using our unsupervised integrative metavariable model (iMVM). Univariate/multivariate analysis were performed for overall survival, grades and mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,